195 related articles for article (PubMed ID: 26493492)
1. Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study.
Posadas EM; Ahmed RS; Karrison T; Szmulewitz RZ; O'Donnell PH; Wade JL; Shen J; Gururajan M; Sievert M; Stadler WM
Prostate; 2016 Feb; 76(3):286-93. PubMed ID: 26493492
[TBL] [Abstract][Full Text] [Related]
2. Phase II trial of saracatinib (AZD0530), an oral SRC-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer.
Gucalp A; Sparano JA; Caravelli J; Santamauro J; Patil S; Abbruzzi A; Pellegrino C; Bromberg J; Dang C; Theodoulou M; Massague J; Norton L; Hudis C; Traina TA
Clin Breast Cancer; 2011 Oct; 11(5):306-11. PubMed ID: 21729667
[TBL] [Abstract][Full Text] [Related]
3. Phase II study of saracatinib (AZD0530) in patients with previously treated metastatic colorectal cancer.
Reddy SM; Kopetz S; Morris J; Parikh N; Qiao W; Overman MJ; Fogelman D; Shureiqi I; Jacobs C; Malik Z; Jimenez CA; Wolff RA; Abbruzzese JL; Gallick G; Eng C
Invest New Drugs; 2015 Aug; 33(4):977-84. PubMed ID: 26062928
[TBL] [Abstract][Full Text] [Related]
4. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium.
Mackay HJ; Au HJ; McWhirter E; Alcindor T; Jarvi A; MacAlpine K; Wang L; Wright JJ; Oza AM
Invest New Drugs; 2012 Jun; 30(3):1158-63. PubMed ID: 21400081
[TBL] [Abstract][Full Text] [Related]
5. Effect of the specific Src family kinase inhibitor saracatinib on osteolytic lesions using the PC-3 bone model.
Yang JC; Bai L; Yap S; Gao AC; Kung HJ; Evans CP
Mol Cancer Ther; 2010 Jun; 9(6):1629-37. PubMed ID: 20484016
[TBL] [Abstract][Full Text] [Related]
6. Abiraterone acetate for patients with metastatic castration-resistant prostate cancer progressing after chemotherapy: final analysis of a multicentre, open-label, early-access protocol trial.
Sternberg CN; Castellano D; Daugaard G; Géczi L; Hotte SJ; Mainwaring PN; Saad F; Souza C; Tay MH; Garrido JM; Galli L; Londhe A; De Porre P; Goon B; Lee E; McGowan T; Naini V; Todd MB; Molina A; George DJ;
Lancet Oncol; 2014 Oct; 15(11):1263-8. PubMed ID: 25242048
[TBL] [Abstract][Full Text] [Related]
7. A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study.
Lara PN; Longmate J; Evans CP; Quinn DI; Twardowski P; Chatta G; Posadas E; Stadler W; Gandara DR
Anticancer Drugs; 2009 Mar; 20(3):179-84. PubMed ID: 19396016
[TBL] [Abstract][Full Text] [Related]
8. Intermittent Chemotherapy as a Platform for Testing Novel Agents in Patients With Metastatic Castration-Resistant Prostate Cancer: A Department of Defense Prostate Cancer Clinical Trials Consortium Randomized Phase II Trial of Intermittent Docetaxel With Prednisone With or Without Maintenance GM-CSF.
Aggarwal RR; Beer TM; Weinberg VK; Higano C; Taplin ME; Ryan CJ; Lin AM; Alumkal J; Graff JN; Nordquist LT; Herrera I; Small EJ
Clin Genitourin Cancer; 2015 Jun; 13(3):e191-8. PubMed ID: 25557266
[TBL] [Abstract][Full Text] [Related]
9. Effects of Src kinase inhibition by saracatinib (AZD0530) on bone turnover in advanced malignancy in a Phase I study.
Hannon RA; Finkelman RD; Clack G; Iacona RB; Rimmer M; Gossiel F; Baselga J; Eastell R
Bone; 2012 Apr; 50(4):885-92. PubMed ID: 22245630
[TBL] [Abstract][Full Text] [Related]
10. Docetaxel and prednisone with or without lenalidomide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer (MAINSAIL): a randomised, double-blind, placebo-controlled phase 3 trial.
Petrylak DP; Vogelzang NJ; Budnik N; Wiechno PJ; Sternberg CN; Doner K; Bellmunt J; Burke JM; de Olza MO; Choudhury A; Gschwend JE; Kopyltsov E; Flechon A; Van As N; Houede N; Barton D; Fandi A; Jungnelius U; Li S; de Wit R; Fizazi K
Lancet Oncol; 2015 Apr; 16(4):417-25. PubMed ID: 25743937
[TBL] [Abstract][Full Text] [Related]
11. Everolimus combined with gefitinib in patients with metastatic castration-resistant prostate cancer: Phase 1/2 results and signaling pathway implications.
Rathkopf DE; Larson SM; Anand A; Morris MJ; Slovin SF; Shaffer DR; Heller G; Carver B; Rosen N; Scher HI
Cancer; 2015 Nov; 121(21):3853-61. PubMed ID: 26178426
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of saracatinib (AZD0530), a Src inhibitor, administered orally daily to patients with advanced thymic malignancies.
Gubens MA; Burns M; Perkins SM; Pedro-Salcedo MS; Althouse SK; Loehrer PJ; Wakelee HA
Lung Cancer; 2015 Jul; 89(1):57-60. PubMed ID: 26009269
[TBL] [Abstract][Full Text] [Related]
13. Combating head and neck cancer metastases by targeting Src using multifunctional nanoparticle-based saracatinib.
Lang L; Shay C; Xiong Y; Thakkar P; Chemmalakuzhy R; Wang X; Teng Y
J Hematol Oncol; 2018 Jun; 11(1):85. PubMed ID: 29925404
[TBL] [Abstract][Full Text] [Related]
14. A phase II trial of saracatinib, an inhibitor of src kinases, in previously-treated advanced non-small-cell lung cancer: the princess margaret hospital phase II consortium.
Laurie SA; Goss GD; Shepherd FA; Reaume MN; Nicholas G; Philip L; Wang L; Schwock J; Hirsh V; Oza A; Tsao MS; Wright JJ; Leighl NB
Clin Lung Cancer; 2014 Jan; 15(1):52-7. PubMed ID: 24169259
[TBL] [Abstract][Full Text] [Related]
15. Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC).
Fury MG; Baxi S; Shen R; Kelly KW; Lipson BL; Carlson D; Stambuk H; Haque S; Pfister DG
Anticancer Res; 2011 Jan; 31(1):249-53. PubMed ID: 21273606
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and Safety of Abiraterone Acetate in Elderly (75 Years or Older) Chemotherapy Naïve Patients with Metastatic Castration Resistant Prostate Cancer.
Smith MR; Rathkopf DE; Mulders PF; Carles J; Van Poppel H; Li J; Kheoh T; Griffin TW; Molina A; Ryan CJ
J Urol; 2015 Nov; 194(5):1277-84. PubMed ID: 26151676
[TBL] [Abstract][Full Text] [Related]
17. Real-world cabazitaxel safety: the Italian early-access program in metastatic castration-resistant prostate cancer.
Bracarda S; Gernone A; Gasparro D; Marchetti P; Ronzoni M; Bortolus R; Fratino L; Basso U; Mazzanti R; Messina C; Tucci M; Boccardo F; Cartenì G; Pinto C; Fornarini G; Mattioli R; Procopio G; Chiuri V; Scotto T; Dondi D; Di Lorenzo G
Future Oncol; 2014 May; 10(6):975-83. PubMed ID: 24295376
[TBL] [Abstract][Full Text] [Related]
18. Efficacy of docetaxel-based chemotherapy following ketoconazole in metastatic castration-resistant prostate cancer: implications for prior therapy in clinical trials.
Pond GR; Armstrong AJ; Galsky MD; Wood BA; Leopold L; Sonpavde G
Urol Oncol; 2013 Nov; 31(8):1457-63. PubMed ID: 22552048
[TBL] [Abstract][Full Text] [Related]
19. Phase I/II trial of orteronel (TAK-700)--an investigational 17,20-lyase inhibitor--in patients with metastatic castration-resistant prostate cancer.
Dreicer R; MacLean D; Suri A; Stadler WM; Shevrin D; Hart L; MacVicar GR; Hamid O; Hainsworth J; Gross ME; Shi Y; Webb IJ; Agus DB
Clin Cancer Res; 2014 Mar; 20(5):1335-44. PubMed ID: 24418642
[TBL] [Abstract][Full Text] [Related]
20. Phase II study of the Src kinase inhibitor saracatinib (AZD0530) in metastatic melanoma.
Gangadhar TC; Clark JI; Karrison T; Gajewski TF
Invest New Drugs; 2013 Jun; 31(3):769-73. PubMed ID: 23151808
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
